Cargando…
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
BACKGROUND: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substantially improved patients’ prognosis, drug resistance remains one of the major...
Autores principales: | Klümper, Theresa, Bruckmueller, Henrike, Diewock, Tobias, Kaehler, Meike, Haenisch, Sierk, Pott, Christiane, Bruhn, Oliver, Cascorbi, Ingolf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519530/ https://www.ncbi.nlm.nih.gov/pubmed/32999756 http://dx.doi.org/10.1186/s40164-020-00183-1 |
Ejemplares similares
-
MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells
por: Kaehler, Meike, et al.
Publicado: (2017) -
Germline variants in cancer therapy
por: Kaehler, Meike, et al.
Publicado: (2019) -
Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells
por: Kaehler, Meike, et al.
Publicado: (2022) -
Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021) -
Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population
por: Afsar, Nasir Ali, et al.
Publicado: (2019)